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Abstract The lymphatic system, the network of lym-
phatic vessels and lymphoid organs, maintains the body
fluid balance and ensures the immunological surveillance
of the body. In the adult organism, the de novo formation
of lymphatic vessels is mainly observed in pathological
conditions. In contrast to the molecular mechanisms gov-
erning the generation of the lymphatic vasculature during
embryogenesis, the processes underlying pathological
lymphangiogenesis are less well understood. A genome-
wide screen comparing the transcriptome of tumor-derived
lymphatic endothelial cells with that of blood vessel
endothelial cells identified paralemmin-1 as a protein
prominently expressed in lymphatic endothelial cells.
Paralemmin-1 is a lipid-anchored membrane protein that in
fibroblasts and neurons plays a role in the regulation of cell
shape, plasma membrane dynamics and cell motility. Here,
we show that paralemmin-1 is expressed in tumor-derived
lymphatic endothelial cells as well as in lymphatic endo-
thelial cells of normal, non-tumorigenic tissue. Paralem-
min-1 represses cell migration and delays the formation of
tube-like structures of lymphatic endothelial cells in vitro
by modulating cell-substrate adhesion, filopodia formation
and plasma membrane blebbing. While constitutive genetic
ablation of paralemmin-1 expression in mice has no effect
on the development and physiological function of the
lymphatic system, the loss of paralemmin-1 impaired
tumor-associated lymphangiogenesis. Together, these
results newly identify paralemmin-1 as a protein highly
expressed in lymphatic endothelial cells. Similar to its
function in neurons, it may link the cytoskeleton to the
plasma membrane and thereby modulate lymphatic endo-
thelial cell adhesion, migration and lymphangiogenesis.
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Introduction
After its formation during embryonic and postnatal devel-
opment, the lymphatic vasculature is mostly quiescent.
Lymphatic vessels only grow in a few physiological situ-
ations such as pregnancy. In contrast, a number of disease
conditions are accompanied by the de novo formation of
lymphatic vessels. Pathological lymphangiogenesis, as it is
called, has been shown to occur in wound healing, tissue
repair, inflammation, organ transplant rejection and cancer.
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In cancer, the formation of new lymphatic vessels (lym-
phangiogenesis) has received major attention, as it con-
tributes to disease progression: in cancer patients, increased
levels of lymphangiogenic growth factors and aberrantly
activated lymphangiogenesis and higher lymphatic vessel
densities are associated with lymph node metastasis and
poor prognosis [1–3].
The molecular mechanisms of pathological lymphangio-
genesis are not completely understood. Key players, which
are essential for lymphatic development during embryo-
genesis include the forkhead transcription factor FoxC2 and
the homeodomain transcription factor Prox-1, yet a variety of
factors has been identified to modulate physiological and
pathological lymphangiogenesis [4]. In the case of cancer,
inflammatory cells, bone-marrow-derived progenitor cells
and tumor cells promote lymphangiogenesis by secreting
various lymphangiogenic growth factors, chemokines and
cytokines. These factors, which include VEGF-C, VEGF-D,
VEGF-A, PDGF-BB, FGF, HGF, IL-1b, TNFa and others,
stimulate lymphatic endothelial cell migration, proliferation
and maturation and thus lymphatic vessel growth [5–7].
While the formation of lymphatic vessels is mainly based on
the proliferation and migration of lymphatic endothelial cells
from pre-existing lymphatic vessels, the incorporation of
bone marrow-derived progenitor cells into growing lym-
phatic vessels has also been reported [8–10].
In order to identify new players involved in pathological
lymphangiogenesis, we have performed a genome-wide
transcriptional profiling of lymphatic endothelial cells (LEC)
versus blood vessel endothelial cells (BEC) from normal
tissue and from tumors with activated lymphangiogenesis.
One of the genes preferentially expressed in LEC is para-
lemmin-1 (Palm1). Paralemmin-1, the founding member of
the paralemmin gene family, is a 42 kDa phosphoprotein
anchored in the plasma membrane by its C-terminal lipid tail
[11]. Human and mouse, paralemmin-1 mRNA is differen-
tially spliced to generate a full-length and an exon 8-deleted
isoform [12]. Paralemmin-1 has been first identified in neu-
rons where it is involved in the regulation of spine and syn-
apse formation, presumably by the modulation of filopodia
formation. Neurons depleted of paralemmin-1 develop sig-
nificantly less filopodia and spines, whereas neurons over-
expressing paralemmin-1 exhibit more [13]. Increased
filopodia and process formation and cellular expansion have
been also detected upon paralemmin-1 overexpression in
non-neuronal cells [12]. Process formation depends on
plasma membrane localization. It has therefore been sug-
gested that the role of paralemmin-1 consists in anchoring the
cortical cytoskeleton to the plasma membrane [13, 14].
Here, we have investigated the functional role of para-
lemmin-1 in lymphangiogenesis by gain and loss of func-
tion experiments in cultured LEC in vitro and in mouse
models in vivo. We find that paralemmin-1-depleted LEC
exhibit altered adhesion and spreading behavior, which
leads to increased LEC migration and accelerated forma-
tion of cord-like structures. In constitutive knockout mice,
the loss of paralemmin-1 does not disturb the formation of
the lymphatic vasculature during embryonic and postnatal
development, perhaps due to homeostatic compensation.
However, in a mouse model of tumor lymphangiogenesis,
the absence of paralemmin-1 results in reduced lymphatic
vessel densities, indicating that paralemmin-1 plays a
critical role in tumor lymphangiogenesis.
Results
Paralemmin-1 is expressed in lymphatic endothelial
cells
To identify genes that were specifically expressed by
lymphatic endothelial cells (LEC) during pathological
lymphangiogenesis in a tumor setting, we isolated LEC and
blood vessel endothelial cells (BEC) from pancreatic b-cell
tumors of RIP1Tag2; RIP1VEGF-C double-transgenic
mice and from islets of Langerhans from single-transgenic
RIP1VEGF-C mice. RIP1Tag2 transgenic mice express the
simian virus (SV) 40 large T-antigen (Tag) under the
control of the rat-insulin promoter (RIP) in the b-cells of
the pancreatic islets of Langerhans and develop pancreatic
insulinomas [15]. Transgenic RIP1VEGF-C mice express
the lymphangiogenic factor VEGF-C in pancreatic b-cells
and exhibit increased peri-insular lymphangiogenesis and
lymphatic vessel density in the periphery of islets of Lan-
gerhans [16]. The simultaneous expression of SV40 Tag
and VEGF-C in pancreatic b-cells in double-transgenic
RIP1Tag2; RIP1VEGF-C mice results in the formation of
peritumoral lymphatic vessels (Supplementary Figure 1A)
promoting the occurrence of lymph node metastasis [16].
LEC and BEC were isolated from tumors of 12-week-
old RIP1Tag2; RIP1VEGF-C and from islets of RIP1-
VEGF-C mice by flow cytometry sorting of CD31?Po-
doplanin?Lyve-1? LEC and CD31?Podoplanin-Lyve-1-
BEC from single cell suspensions (Supplementary Fig-
ure 1B). Total RNA was prepared from these cells and
further processed for the subsequent hybridization to DNA
microarrays. The transcriptional profile of LEC isolated
from islets of RIP1VEGF-C and from tumors of RIP1Tag2;
RIP1VEGF-C mice were, as expected, different from islets
and tumors of BEC isolated from the same genotype ani-
mals (Supplementary Figure 1C). Transcript levels of
known LEC and BEC markers were found to be up-regu-
lated in the corresponding transcriptomes (Supplementary
Figure 1D), indicating the successful separation of these
two cell populations by flow cytometry. Comparing the
transcriptome of tumor-derived LEC to that of islet-derived
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LEC, around 500 genes were found differentially expressed
(twofold up or down in expression levels). Among the
genes highly expressed in tumor LEC were genes associ-
ated with cell adhesion, remodeling of the extracellular
matrix, immune response and cell proliferation (Supple-
mentary Table I). Furthermore, the comparison of the
transcriptome of LEC with that from BEC allowed the
identification of genes specifically up-regulated in LEC.
One of the genes specifically expressed in LEC and not
in BEC encoded for paralemmin-1 (Palm1), a neuronal
gene thus far not reported expressed by LEC. Quantitative
RT-PCR revealed that its mRNA levels were 13-fold
higher in LEC as compared to BEC. To confirm the
microarray and RT-PCR results, the expression of para-
lemmin-1 was analyzed by immunofluorescence micros-
copy. Cryosections of pancreata from RIP1VEGF-C and
RIP1Tag2; RIP1VEGF-C mice were co-stained for para-
lemmin-1 and for common LEC markers, such as Lyve-1,
Podoplanin and Prox-1. Paralemmin-1 co-localized with all
three LEC markers, indicating that tumor-derived and islet-
associated LEC expressed paralemmin-1 (Fig. 1). Next,
cryosections of skin, diaphragm, heart, pancreas, intestine
and tail obtained from normal C57Bl/6 mice were stained
for paralemmin-1 and Lyve-1 to assess whether paralem-
min-1 was also expressed by the lymphatic vasculature of
normal tissue and organs. In all tissues and organs, Lyve-1-
positive LEC also stained positive for paralemmin-1
(Fig. 2a). To distinguish blood vessels from lymphatic
vessels, C57Bl/6 mice were perfused with FITC-lectin
prior to sacrifice, and tissue and organs were stained for
paralemmin-1. In contrast to the lymphatic vasculature,
FITC-lectin-labeled blood vessels did not co-localize with
paralemmin-1 expression (Fig. 2b). Together, these results
show that paralemmin-1 is specifically expressed both in
activated as well as in quiescent LEC of the lymphatic
vasculature but not in BEC of the blood vasculature.
Paralemmin-1 modulates LEC adhesion and migration
To assess the function of paralemmin-1 in LEC, paralem-
min-1 expression was down-regulated in the two murine
lymphatic endothelial cell lines SV-LEC and MELC using
RNA interference [17, 18]. SV-LEC as well as MELC
expressed the two known isoforms of paralemmin-1 as
determined by immunoblotting and quantitative RT-PCR
analysis (Supplementary Figures 2A, B, 3A). In SV-LEC,
48 h after transfection with two different siRNAs against
paralemmin-1 [siPalm (1) and (2)], mRNA and protein
levels of both paralemmin-1 isoforms were reduced by
75 % compared to SV-LEC transfected with a control
siRNA (siCont; Supplementary Figure 2A). In MELC,
stably transfected with shRNAs targeting paralemmin-1
[shPalm (1) and (2)], mRNA and protein levels of
paralemmin-1 could be reduced to around 50 % (Supple-
mentary Figure 2B). In contrast to SV-LEC, in MELC the
two isoforms were not equally reduced. Besides paralem-
min-1, SV-LEC and MELC express high levels of para-
lemmin-2 and, to a lesser extent, paralemmin-3 and 4
(Supplementary Figure 3A). Ablation of paralemmin-1
expression did not affect the expression of the other para-
lemmin family members (Supplementary Figure 3B).
In a Boyden chamber assay, SVLEC and MELC with
reduced paralemmin-1 levels migrated significantly faster
than control cells (Fig. 3a, b). Increased migration velocity
may account for the accelerated formation of cord-like
structures in Matrigel (Fig. 3c, d). Sixty minutes after
seeding on Matrigel, the majority of paralemmin-1-deple-
ted cells were attached to each other and started to form
Fig. 1 Paralemmin-1 is expressed in activated and tumor-derived
lymphatic endothelial cells. Representative immunofluorescence
microscopy pictures of pancreatic sections from RIP1VEGF-C (left)
and RIP1Tag2; RIP1VEGF-C (right) mice stained for paralemmin-1
(red) and for the lymphatic endothelial cell markers Lyve-1 (upper
row), podoplanin (middle row) and Prox-1 (lower row). Nuclei were
visualized by DAPI staining. Scale bars 100 lm. I = islet,
T = tumor, E = exocrine pancreas
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cord-like structures, whereas approximately 90 % of the
control cells were still found as single cells at this time
point. An hour later, also the majority of the control cells
were incorporated into cord-like structures.
Since changes in adhesion strength can directly influ-
ence cell migration [19–21], we next assessed whether the
depletion of paralemmin expression alters LEC adhesion
and spreading on solid substrates using live cell interfer-
ence reflection microscopy (IRM). With IRM, the spread-
ing and adhesion of cells on the glass surface of the slide
can be quantified and followed over time. After adhesion
and spreading on a glass coverslip, control siRNA-trans-
fected (siCont) SV-LEC switched between cell expansion
and retraction, while the average total adhesion area
remained constant (Fig. 4a). The initial adhesion and
spreading phase of knockdown (siPalm) and control cells
was comparable. However, after spreading, 56–78 % of the
paralemmin-1-deficient cells ‘‘contracted’’ and decreased
their adhesion areas, a behavior found in only 4 % of the
control SV-LEC (Fig. 4b). Moreover, all ‘‘contracted’’
paralemmin-1-depleted cells exhibited a high and dynamic
membrane blebbing activity, which was almost completely
absent in control SV-LEC. Finally, paralemmin-1-depleted
cells formed less filopodia as compared to control cells
(Fig. 4c, upper panels).
The adhesion and spreading behavior of control and
transient paralemmin-1 knockdown SV-LEC was also
examined under more physiological conditions by plating
the cells on cover slips coated with parallel 12 lm-wide
fibronectin lines. The zones between the lines were coated
with PLL-PEG as an anti-adhesive substance. This 1D
substrate forces cells into an uni-axial morphology and
rapid unidirectional movement similar to what is observed
in 3D matrices consisting of collagen fibers [22]. On
fibronectin-coated lines, both control and paralemmin-1
knockdown cells assumed a uni-axial morphology with
lamellipodia at the migrating front (Fig. 4c, lower panels).
However, only paralemmin-1 knockdown SV-LEC showed
membrane blebbing along their sides, whereas in control
SV-LEC the plasma membranes formed straight lines with
strong parallel cortical actin fibers. The appearance of
plasma membrane blebs in paralemmin-1 knockdown cells
could be the result of a destabilization of the interaction
between the plasma membrane and the cytoskeleton.
Indeed, immunofluorescence staining for actin and paxillin
revealed that the cell protrusions of paralemmin-1-depleted
cells possessed less stress fibers and focal adhesion sites
(Supplementary Figure 4).
Taken together, these results show that paralemmin-1
exerts a critical role in substrate adhesion and motility of
LEC, conceivably by modulating the interaction between
the plasma membrane and the actin cytoskeleton.
Loss of paralemmin-1 affects pathological
lymphangiogenesis
To determine the role of paralemmin-1 in LEC in vivo, we
first analyzed constitutive paralemmin-1 knockout (Palm-/-)
mice. Palm-/- mice appeared healthy, fertile and showed no
overt phenotype. Importantly the mice did not display any
Fig. 2 Paralemmin-1 is expressed in lymphatic endothelial cells and
not in blood vessel endothelial cells. a Representative immunofluo-
rescence microscopy pictures of histological sections from six tissues
of C57Bl/6 mice stained for the LEC marker Lyve-1 (green) and
paralemmin-1 (red). Nuclei were visualized with DAPI.
b Immunofluorescence staining for paralemmin-1 (red) of sections
of four tissues isolated from C57Bl/6 mice perfused with the FITC-
lectin to visualize functional blood vessels. Nuclei were counter-
stained with DAPI. Scale bars 100 lm
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sign of lymphedema indicating that their lymphatic system
was functional. Histological sections of various organs
stained for Lyve-1 and CD31 demonstrated a normal lym-
phatic network and lymphatic vessel structure in Palm-/-
mice (Fig. 5a). Whole-mount staining for Lyve-1 of the ear
and diaphragm confirmed that the number and the structure of
the lymphatic vessels in Palm-/- mice were comparable to
those in C57Bl/6 control mice (Fig. 5b). The Lyve-1-positive
lymphatic vessels of wildtype and knockout animals had
similar diameter and length and they displayed a comparable
degree of complexity (Fig. 5b).
Next, we examined whether the lymphatic vessels in
paralemmin-1-/- mice were functional in draining water-
soluble dyes from the peripheral tissue. First, Chicago Blue
was injected into the hind footpad of control C57Bl/6 and
Palm-/- mice, and its drainage to the popliteal lymph
nodes was monitored. Indeed, some minutes after injection,
in both control and Palm-/- mice the popliteal lymph node
was stained blue (Fig. 6a). Second, low-molecular weight
FITC-Dextran was injected into the tip of the tail, and
uptake and transport of FITC-Dextran was followed under
a fluorescent stereomicroscope. The transport of FITC-
Dextran by the tail lymphatic vasculature occurred with
similar speed and efficiency in both control Palm?/? and
Palm-/- mice (Fig. 6b). These data indicate that para-
lemmin-1 is not required for the structure and physiological
function of the lymphatic vasculature in adult mice.
Based on the observation that the lack of Palm-/- in
LEC led to accelerated cell migration and formation of
cord-like structures, there could be a quantitative differ-
ence during the embryonic and postnatal development of
the lymphatic vasculature. Hence, we investigated the
development of the lymphatic network in the tail and the
intestine of normal control mice and paralemmin-1-/-
mice, which occurs after birth and follows distinct steps. In
the tail, the formation of the superficial dermal lymphatic
network starts with the generation of an irregular and dis-
continuous network of vessels which develop within 6 days
Fig. 3 Knockdown of
paralemmin-1 expression in
cultured lymphatic endothelial
cells leads to increased cell
migration, and to the
accelerated formation of cord-
like structures upon three-
dimensional culture in Matrigel.
a Cell migration of SV-LEC and
control (siCont) cells ablated for
paralemmin-1 expression by
transient transfection with
siRNAs against paralemmin-1
[siPalm (1) and (2)] determined
in a Boyden chamber assay.
** p \ 0.01; *** p \ 0.001
(Student’s t test). b Cell
migration of MELC and control
(shCont) cells ablated for
paralemmin-1 expression by the
stable expression of shRNAs
against paralemmin-1 [shPalm
(1) and (2)] determined in a
Boyden chamber assay.
** p \ 0.01 (Student’s t test). c,
d Light microscopy images
(left) and quantification (right)
of the formation of cord-like
structures upon three-
dimensional culture in Matrigel.
SV-LEC were transiently
depleted of paralemmin-1
(upper panel) and MELC were
stably depleted of paralemmin-1
expression (lower panel) as
described in (a) and (b). One
representative experiment is
shown. Scale bars 100 lm
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into the highly organized hexagonal lattice [23]. Tails and
intestine of newborns at day P0, P2 and P8 were stained in
whole mount for Lyve-1 (Fig. 6c). Comparing Palm?/?
and Palm-/- mice, the formation of the lymphatic network
in the tail and of the intestinal villi, the so-called lacteals,
was not affected by the lack of paralemmin-1.
Next we assessed whether paralemmin-1 was required for
lymphangiogenesis in the adult organism. To this end,
Palm-/- mice were crossed with RIP1VEGF-C mice and
RIP1Tag2; RIP1VEGF-C mice to generate RIP1VEGF-C;
Palm-/- and RIP1Tag2; RIP1VEGF-C; Palm-/- mice.
Pancreatic sections from these mice were then stained for
Lyve-1 and CD31 and the stained area were quantified for
blood microvessels density and lymphatic coverage of islets
of Langerhans and of pancreatic insulinomas, respectively.
The lymphatic coverage of the islet of Langerhans as well as
the blood microvessel density in islets were comparable
between RIP1VEGF-C; Palm?/? and RIP1VEGF-C;
Palm-/- mice (Supplementary Figure 5). In the RIP1Tag2;
RIP1VEGF-C; Palm-/- mice, the loss of paralemmin-1 did
not change the number of pancreatic tumors nor did it
influence tumor volumes or intra-tumoral blood microvessel
densities as compared to RIP1Tag2; RIP1VEGF-C; Palm?/?
mice (Fig. 7a, Supplementary Figure 6). However, the
lymphatic coverage of the tumors was significantly reduced
in RIP1Tag2; RIP1VEGF-C; Palm-/- mice compared to
RIP1Tag2; RIP1VEGF-C; Palm?/? mice (Fig. 7b, c). These
data indicate that, while paralemmin-1 may not be required
for physiological lymphangiogenesis, it is required for tumor
lymphangiogenesis.
Discussion
We have identified paralemmin-1 to be prominently
expressed by LEC of the lymphatic vasculature of various
tissue types and organs. This paralemmin-1 staining,
abolished in Palm-/- mice, co-localized with the staining
for the widely used LEC markers Prox-1, Lyve-1 and Po-
doplanin, indicating that paralemmin-1 can serve as a new
Fig. 4 Knockdown of
paralemmin-1 expression in
cultured lymphatic endothelial
cells affects cell adhesion,
spreading, blebbing and
filopodia formation. a SV-LEC
were transiently transfected
with control siRNA (siCont) or
siRNAs against paralemmin-1
[siPalm (1) and siPalm (2)], and
cell spreading on poly-L-lysine
substratum was quantified by
live cell reflection interference
contrast microscopy (RICM).
b Contraction of SV-LEC after
cell spreading on poly-L-lysine
substratum was quantified by
differential interference contrast
microscopy (DICM).
c Representative DICM images
of control and paralemmin-1
knockdown SV-LEC taken
during cell spreading on poly-L-
lysine (upper panels) and after
plating on glass slides coated
with single 10 lm fibronectin
lines next to anti-adhesive
coating (lower panels). Scale
bars 10 lm
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marker of LEC. In contrast, paralemmin-1 expression was
not detected in BEC of various tissues investigated, indi-
cating that blood endothelia do not express paralemmin-1
or at least at much lower levels than lymphatic endothelia.
Previously, paralemmin-1 has been described by immun-
operoxidase staining in subpopulations of blood endothelia
of rat kidney and adrenal gland, though not brain [24], and
of human mammary gland and breast cancers [25]. More
comprehensive investigations will be needed to clarify in
which types of blood vessels, under which physiological
conditions, at which relative levels and by which tech-
niques paralemmin-1 can be detected in BEC.
In LEC, paralemmin-1 may be involved in the regula-
tion of the interaction between the plasma membrane and
the actin cytoskeleton, as previously suggested for neurons
and fibroblasts [12]. Ablation of paralemmin-1 expression
in LEC leads to increased migration velocity and to an
accelerated formation of cord-like structures upon 3D
culture in Matrigel. Increased migration speed of para-
lemmin-1-deficient cells appears to be caused by a reduc-
tion in cell-substrate adhesion and an altered spreading
behavior. This observation is consistent with previous
reports demonstrating that lowering adhesion strength
correlates with an increased cell speed, and vice versa [20,
21]. On surfaces with low adhesive properties, including
glass slides, paralemmin-1-deficient LEC fail to properly
adhere and to form filopodia, they rather contract and start
to form plasma membrane blebs. The increased plasma
membrane blebbing itself may also further contribute to the
increase in migration speed by adapting to a more amoe-
boid form of cell migration [26], as can be seen with
paralemmin-1-deficient cells that exhibit reduced focal
adhesion sites and stress fibers.
The molecular mechanisms by which paralemmin-1
modulates these processes are not known. Adhesion of
cells to the extracellular matrix (ECM) is initiated by
binding of integrins to components of the ECM. We
speculate that paralemmin-1 plays a critical role in the
modulation of the recruitment of signaling molecules and
actin-binding proteins to clustered integrins which finally
leads to a reorganization of the actin cytoskeleton and the
formation of filopodia and lamellipodia [27]. Our analysis
has shown that paralemmin-1 is not required for the initial
binding of LEC cells to surfaces. However, cell spreading,
Fig. 5 Constitutive paralemmin-1 knockout mice (Palm-/-) have
normal lymphatic system morphology. a Representative immunoflu-
orescence staining of histological sections of various tissue from
C57Bl/6 (Palm?/?; left) and Palm-/- (right) mice stained for CD31
(BEC marker, green) and Lyve-1 (LEC marker, red). Nuclei were
visualized with DAPI. Scale bars 100 lm. b Whole mount staining
for Lyve-1 of the ear and diaphragm from Palm?/? and Palm-/- mice
to visualize the lymphatic system in these organs. Scale bars 100 lm
b
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focal adhesion, reorganization of the actin cytoskeleton and
the formation of membrane protrusions are impaired by the
lack of paralemmin-1. A similar effect on the actin cyto-
skeleton has been observed in neurons where down-regu-
lation of paralemmin-1 expression decreases the formation
of filopdia [13]. Conversely, the forced expression of
paralemmin-1 increases membrane protrusion formation in
neuronal and also in non-neuronal cells [12, 13]. Based on
these results it is likely that paralemmin-1 acts as a linker
between the plasma membrane and the cytoskeleton, nec-
essary for the transduction of outside signals into cells.
Whether paralemmin-1 plays a direct role in the recruit-
ment of signaling molecules to the sites of action needs
further investigation. In neurons, paralemmin-1 is involved
in the recruitment of AMPA-type glutamate receptors and
it interacts with D3 dopamine receptors [13, 28]. Also,
paralemmin-3 has been found to bind single immuno-
globulin IL-1 receptor-related molecule (SIGIRR), a neg-
ative regulator of Toll-Interleukin-1 receptors, and thereby
to modulate LPS-stimulated inflammatory responses [29].
Although paralemmin-1 has been found both in non-
proliferating as well as in activated, proliferating LEC, its
function in the development and physiology of the lym-
phatic system in vivo remains elusive. Our analysis of
constitutive paralemmin-1 knockout (Palm-/-) mice indi-
cates that paralemmin-1 is not required for the
Fig. 6 The lymphatic system in paralemmin-1 knockout mice
(Palm-/-) is functional. a Images of popliteal lymph nodes of control
Palm?/? mice (upper panel) and Palm-/- mice (lower panel) 8 min
after footpad injection of Chicago Blue. b Lymphatic drainage of
FITC-Dextran injected in the tail tip of Palm?/? and Palm-/- mice.
Fluorescence microscopy pictures were taken 2 min after injection.
c Loss of paralemmin-1 does not disturb lymphatic vasculature
development. Whole-mounts of tail (left) and intestine (right) from
Palm?/? and Palm-/- mice at the day of birth (P0) or 2 and 8 days
after birth (P2, P8) were stained with antibodies against Lyve-1.
Representative fluorescence microscopy pictures are shown. Scale
bars 100 lm
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development and the physiological function of the lym-
phatic system. Since paralemmin-1 is expressed during the
postnatal development of the lymphatic system in the
intestine and the tail, the lack of ‘‘a developmental
lymphatic phenotype’’ in Palm-/- mice may be due to
compensating functions of other paralemmin family
members expressed in LEC or due to paralemmin-inde-
pendent homeostatic mechanisms. Preliminary results
showed that LECs isolated from the skin of newborn
Palm-/- mice have increased paralemmin-2 and para-
lemmin-4 (also termed palmdelphin) mRNA levels
compared to their levels in control LEC (Supplementary
Figure 7). Structurally, paralemmin-2 and paralemmin-4
share similarities with paralemmin-1 [30], including the
C-terminal CAAX lipidation motif which is essential for
the plasma membrane localization of these proteins.
Whether these similarities translate into a similar mode
of action remains to be assessed. Also in the adult
organism, the redundancy of several paralemmin family
members or heterologous compensation may explain why
lymphangiogenesis in the non-tumorigenic RIP1VEGF-C
mice is independent of the presence of paralemmin-1. In
contrast, tumor lymphangiogenesis in RIP1Tag2; RIP1-
VEGF-C mice, a highly acute process of lymphatic
vessel formation, is clearly dependent on the presence of
paralemmin-1. Together, our data indicate that paralem-
min-1, with its regulation of LEC adhesion, migration
and maturation and with its critical role in tumor lym-
phangiogenesis, is a novel marker for LEC and lym-
phatic vessels and a potential therapeutic target to
Fig. 7 Paralemmin-1 is required for pathological lymphangiogenesis.
a Quantification of the intratumoral CD31-positive blood microvessel
density in 12 week-old RIP1Tag2; RIP1VEGF-C; Palm?/? mice
(N = 5, n = 109) and RIP1Tag2; RIP1VEGF-C; Palm-/- mice
(N = 5, n = 91) was performed using computer-assisted image
analysis. Results are displayed as percentage of CD31-stained area
to total tumor area. b Quantification of the Lyve-1-positive lymphatic
coverage of tumors, shown as percentage of the total tumor perimeter,
in RIP1Tag2; RIP1VEGF-C; Palm?/? mice (N = 5, n = 66) and
RIP1Tag2; RIP1VEGF-C; Palm-/- mice (N = 5, n = 69).
*** p \ 0.0001 (Student’s t test). N = number of mice, n = number
of tumors. Standard deviations (SD) are depicted. c Representative
immunofluorescence microscopy pictures of pancreatic tumor sec-
tions of RIP1Tag2; RIP1VEGF-C; Palm?/? and RIP1Tag2; RIP1-
VEGF-C; Palm-/- mice stained for Lyve-1 (green) and CD31 (red).
Nuclei were visualized with DAPI. Scale bars 50 lm
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interfere with tumor lymphangiogenesis and to prevent
lymph node metastasis.
Materials and methods
Mouse work
All experimental procedures involving mice were approved
by and performed according to the guidelines and regula-
tions of the local committees for animal care (The Swiss
Federal Veterinary Office (SFVO) and the Cantonal Vet-
erinary Office of Basel-Stadt, permit number 1878). Con-
stitutive paralemmin-1 knockout (Palm-/-) mice were
generated by targeted deletion of exon 5, causing a reading
frame shift, by TaconicArtemis (Ko¨ln, Germany). Western
blot analysis demonstrated that this is a null mutation, with
protein expression in brain undetectable (detection
limit \ 1 % of WT level). Gene construct design and KO
mouse analysis will be described in more detail elsewhere.
Palm-/- mice were crossed with single-transgenic RIP1-
VEGF-C or double-transgenic RIP1Tag2; RIP1VEGF-C
[16] to obtain RIP1VEGF-C; Palm-/- or RIP1Tag2;
RIP1VEGF-C; Palm-/- mice, respectively. All mice were
kept on a C57Bl/6 background.
Lymphatic drainage in the tail was analyzed by injection
of 2 ll of 10 % FITC Dextran (2,000,000 MW, Invitrogen)
dissolved in PBS into the tail tip of anaesthetized C57Bl/6
control and Palm (-/-) mice. Five minutes after injection,
pictures of the tails were taken using a fluorescent stereo-
microscope (Nikon SMZ 1500, Nikon LH-M100CB-1
camera). For the examination of the lymphatic drainage to
the popliteal lymph node, 10 ll of a 1 % Chicago Blue dye
solution (Sigma-Aldrich) were injected into the hind foot-
pad of the mice. After 8 min, the mice were sacrificed, the
popliteal lymph nodes were dissected and pictures were
taken using a Nikon SMZ 1500 microscope.
To evaluate the functionality of blood vessels, 100 ll of
fluorescein-labeled Lycopersicon esculentum lectin (1 mg/
ml, Vector Laboratories) in PBS were injected in the tail vein
of anaesthetized mice. Five minutes after injection, mice
were heart-perfused with 10 ml 4 % paraformaldehyde in
PBS and 10 ml PBS, and subsequently the pancreata were
isolated. The phenotypical analysis of RIP1VEGF-C;
Palm-/-, RIP1Tag2; RIP1VEGF-C; Palm-/- and their
respective littermate control mice were performed between
the age of 4 and 12 weeks. In tumor-bearing mice (RIP1-
Tag2; RIP1VEGF-C; Palm?/? and RIP1Tag2; RIP1VEGF-
C; Palm-/-), tumor incidence was determined per mouse by
counting all macroscopically visible pancreatic tumors with
a diameter above 1 mm. The tumor volume was calculated
from the measured tumor diameter assuming a spherical
shape of the tumor.
Isolation of dermal lymphatic endothelial cells
Skin of newborns (age P0-P6) of control and Palm-/- mice
was isolated and then incubated in PBS supplemented with
20 mM EDTA for 2 h at 37 C. After separation of the
epidermis from the dermis, skin was cut into small pieces
and digested in a dispase/collagenase solution for 1 h at
37 C. Indigested material was removed by filtration and
the single cells were washed in PBS and resuspended in
HUVEC media (M199 containing 80 U/ml heparin, 40 mg/
ml bovine brain protein extract, 20 % FBS, 4 mM Gluta-
min) and plated on a gelatin-coated cell culture dish. The
following day, adherent cells were removed from the cell
culture plate by treatment with Accutase. For the sub-
sequent isolation by flow-cytometry, the cells were stained
with hamster anti-mouse podoplanin/anti-hamster IgG PE
(Invitrogen), rat anti-mouse FITC-CD31 (BD Pharmingen)
and rat anti-mouse CD45 (BD Pharmingen). Total RNA
was extracted from isolated CD31?Podoplanin?CD45-
LECs using the Absolutely RNA Nanoprep Kit (Strata-
gene), reverse transcribed into cDNA and analyzed by
semiquantitative and quantitative PCR.
Gene expression profiling
Single cell suspensions of pancreatic tumors of 12-week
old RIP1Tag2; RIP1VEGF-C and islets of RIP1VEGF-C
mice were prepared by dispase digestion. For subsequent
isolation of tumor-derived CD31?Podoplanin?Lyve-1?
LEC and CD31? BEC by flow cytometry, cells were
stained with hamster anti-mouse podoplanin (Hybridoma
supernatant, clone 8.1.1)/anti-hamster IgG488 (Invitrogen),
rat-anti mouse PE-CD31 (BD Pharmingen) and biotinyla-
ted rabbit anti-mouse Lyve-1 (Reliatech)/Streptavidin-APC
(Invitrogen). Total RNA was extracted from isolated cells
using the Absolutely RNA Nanoprep Kit (Stratagene),
amplified in two rounds, IVT-labeled, fragmented and
hybridized to Mouse 430 A2.0 microarrays (Affymetrix).
Histopathological analysis
For histopathological analysis, the isolated organs were
fixed in 4 % paraformaldehyde (Sigma) for 2 h at 4 C,
then incubated over night in 30 % sucrose in PBS and
finally embedded in OCT (Tissue Tek). Immunostaining
was performed on 7 lm cryosections. After cutting, tissue
sections were placed on slides, washed with PBS and then
blocked for 60 min at RT with 5 % goat serum in PBS.
Sections were incubated for 60 min with primary anti-
bodies diluted in blocking buffer, washed with PBS and
incubated with secondary antibodies diluted in blocking
buffer. After 30 min, sections were washed with PBS,
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nuclei were counterstained with 6-diamidino-2-phenylin-
dole (Sigma) and slides were mounted.
The following antibodies were used: rabbit anti-mouse
paralemmin-1 [24], rabbit anti-mouse Prox-1 (obtained
from K. Alitalo, University of Helsinki, Finland), hamster
anti-mouse podoplanin (Hybridoma supernatant, clone
8.1.1), rabbit anti-mouse Lyve-1 (Reliatech), rat anti-
mouse CD31 (BD PharmingenTM), guinae pig anti-mouse
insulin (Dako), rabbit anti-human paxillin (Abcam) and
AlexaFluor 568 phalloidin (Invitrogen). Secondary anti-
bodies were conjugated either with Alexa Fluor 488 or 568
(Invitrogen). Viewing of stained sections and picture
acquisition was done on a Leica DMI 4000 fluorescence
microscope or a Zeiss LSM 510 Meta laser scanning
confocal microscope. Microvessel density and lymphatic
coverage of islets and tumors were quantified using ImageJ
software (Rasband, W.S., Image J, U. S. National Institutes
of Health, Bethesda, Maryland, USA, http://rsb.info.nih.
gov/ij/, 1997–2007) and are displayed as % of CD31-
positive stained area of total islet or tumor area and of
stained Lyve-1-postive perimeter to total islet or tumor
perimeter, respectively.
Whole mount staining
Whole-mount staining was performed with tail and intes-
tine of newborn as well as with ear and diaphragm of adult
C57Bl/6 control and Palm-/- mice. Organs were isolated,
cut into small pieces and fixed in 4 % paraformaldehyde in
PBS for 4 h at RT. After washing, tissue were blocked in
5 % goat serum, 0.2 % BSA, 0.3 % Triton X-100 in PBS
O/N at 4 C, followed by over night incubation with rabbit
anti-mouse Lyve-1 (Reliatech) antibody diluted in blocking
solution. After 5 washes with 0.3 % Triton X-100, PBS for
20 min at RT, tissue were incubated with anti-rabbit fluo-
rophore-conjugated antibody diluted in blocking solution.
After 5 h incubation, tissue were washed three times with
0.3 % Triton X-100, PBS for 15 min at RT, then fixed for
5 min with 4 % paraformaldehyde in PBS, washed with
PBS three times for 5 min at RT and mounted with Moviol.
Picture stacks of the stained organs were acquired on a
Zeiss, LSM 510 Meta confocal microscope and converted
into 3D images using Imaris Software (Bitplane).
Cell culture
The mouse lymphatic endothelial cell lines SV-LEC and
MELC were obtained from J.S. Alexander (Louisiana State
University, USA) and A. Vecchi (Mario Negri Institute,
Milan, Italy), respectively. Both cell lines were cultured as
previously described [17, 18]. For the generation of tran-
sient paralemmin-1 knockdown cells, cells were
transfected with siControl, siPalm (1) or siPalm (2)
(Sigma) with a final concentration of 10 nM. Transfection
of SV-LEC was performed with LipofectamineTM RNAi-
MAX (Invitrogen) reagents following the manufacturer’s
instructions. Paralemmin-1 expression was analyzed by
quantitative RT-PCR and immunoblotting. Stable para-
lemmin-1 knockdown MELC were generated using a len-
tiviral transduction system. Lentiviral particles with the
expression vectors pLenti-shPalm (Sigma) were generated
in HEK293T cells. Cells were transfected with the
expression vector using FuGENE HD Transfection
Reagent (Roche) according to the manufacturer’s protocol.
Sixty hours after transfection, the supernatant of the
transfected HEK293T cells containing the viral particles
was filtered through a 0.45 lm filter (Millipore), diluted
1:1 with normal growth medium and added to the MELC
for 24 h. The infection was repeated once and infected
cells were selected with 5 ng/ll puromycin (Sigma) for
1 week. Paralemmin-1 expression was analyzed by quan-
titative RT-PCR and immunoblotting and stable shPalm
MELC and control cells were used for further functional
analysis. For immunofluorescence stainings, cells were
seeded on glass slides or cell culture dishes and then fixed
with 4 % paraformaldehyde for 10 min at 37 C. Sub-
sequent stainings were performed as described in the sec-
tion ‘Histopathological analysis’.
Semiquantitative and quantitative RT-PCR
Total RNA was extracted from cells or from tissues using
Trizol reagent (Sigma), and reverse-transcribed in cDNA
with random hexamer primers using ImProm-IITM Reverse
Transcriptase (Promega). RNA from flow cytometry-sorted
cells was extracted with the Absolutely RNA Nanoprep Kit
(Stratagene) and amplified prior PCR analysis using the
WT-Ovation Pico RNA amplification (NuGEN Technolo-
gies, Inc.). mRNA transcript levels were quantified on a
StepOnePlus Real Time PCR System (Applied Biosys-
tems) with SYBR Green Master mix (Eurogentec). Tran-
script expression levels were normalized against the house-
keeping genes mouse guanosine disphosphate dissociation
inhibitor 2 (mGDI2) or mouse TATA-box-binding protein
(mTbP) and were displayed as DCT values or fold changes.
Primers for semi-quantitative PCR: mPalm1: fwd: 50-AAA
GAGAATCGCACGTCCAC-30, rev: 50-TCGCTCAGTGT
GACCTCATC-30; mPalm2: fwd: 50-CTGCCTTCTAGGA
CCACCTG-30, rev: 50-CATTCTCTCGCGCCTTTTAG-30;
mPalm3: fwd: 50-ATTCGCAACCTGGAAGACAG-30, rev:
50-GGAAGTTCGCTTGTCCACAT-30; mPalm4 (Palmd):
fwd: 50-TTGGACTTCCTTCAGCGTCT-30, rev: 50-TGCTG
GTCTTGCTGATTTTG-30; mActin: fwd: 50-ACACTGT
GCCCATCTACGAGG-30, rev: 5-CATGCATGCCACAGG
ATTCC-30.
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Primers for quantitative PCR: mPalm1: fwd: 50-CGACG
AGGACATGAGGAAAC-30, rev: 50-TCTCCAAACTCCA
GAACATCG-30; mPalm2: fwd: 50-GAAGATGAATTCAA
AGTCAAGC-30, rev: 50-TTTCGAGCGCTTGTATTTCC-
30; mPalm3: fwd: 50-ACACAGACCTGCTGGTAGGC-30,
rev: 50-AGTTCGCTTGTCCACATCAGT-30; mPalm4:
fwd: 50-AAATTGAAACACCAACATCTGAAG-30, rev:
50-CTTTTCCACTGCCGATTCC-30; mGDI2: fwd: 50-CC
CTATCAAGAACACCAACGA-30, rev: 50-TGCAAAGG
AGATCATGCAAA-30; mTbp: fwd: 50-CTGGAATTGT
ACCGCAGCTT-30, rev: 50-TCCTGTGCACACCATTTT
TC-30; mCD31: fwd: 50-GGAGTCAGAACCCATCAGG
A-3‘, rev: 5‘-TACTGG GCTTCGAGAGCATT-30; mProx-
1: fwd: 50-AAGTGGTTCAGCAATTTCCG-3‘, rev: 50-TG
ACCTTGTAAATGGCCTTC-30; mLyve-1: fwd: 50-TTCC
TCGCCTCTATTTGGAC-30, rev: 50-ACGGGGTAAAAT
GTGGTAAC-30; mNG2: fwd: 50-TGATTCCTTCTCCCT
GGATG-30.
Immunoblotting
Cells and tissue were lysed in ice-cooled RIPA-plus buffer
[50 mM Tris–HCl pH 8, 150 mM NaCl, 2 mM MgCl2,
2 mM CaCl2, 0.5 % NaDoc, 10 % glycerol, 1 % NP40,
0.1 % SDS, 1 mM NaF, 2 mM NaVO4, 1 mM DTT, and
protease inhibitor cocktail (Sigma)]. Cleared protein lysates
were separated by SDS-PAGE, transferred on PDVF mem-
branes and stained for paralemmin-1 and tubulin (Sigma).
Migration assay
25 9 103 of control and paralemmin-1 knockdown cells
resuspended in 100 ll DMEM, 0.5 % FBS were plated in the
transwell insert (pore size 8 lm, Falcon, Becton–Dickin-
son) which was placed afterwards in a 24-well plate (Fal-
con, Becton–Dickinson) filled with 500 ll complete
growth medium. Cells were allowed to migrate for 6 h at
37 C. Subsequently cells were fixed with 4 % paraformal-
dehyde (Sigma), nuclei were stained with DAPI (5 lg/ml,
Sigma) and non-migrated cells were removed with a cotton
swab. Pictures were taken with a fluorescence microscope
(Leica DMI 4000) at 109 magnification and the total number
of cells was counted in 5 fields by ImageJ software (Rasband,
W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2012).
Each experiment was done in triplicates, and one represen-
tative experiment is shown.
Cord formation assay
The ability of endothelial cells to form cord-like structures
on Matrigel (growth factor reduced, high concentration,
BD Biosciences) was studied using l-slides (ibidi). 10 ll
Matrigel was added per well, and after solidification of
Matrigel by incubation at 37 C for 20 min, 12.5 9 103
control or paralemmin-1 knock-down cells resuspended in
50 ll complete growth medium were layered on top. After
1 h and 2 h incubation at 37 C, pictures were taken by a
light microscope (Leica DMIL) at 109 magnification. The
cells outside cord-like structures were counted manually
and related to the total seeded cell number. Each experi-
ment was done in triplicates, and one representative
experiment is shown.
Live cell imaging
The adhesion and spreading behavior of LEC upon loss of
paralemmin-1 was studied in a Ludin chamber (Life
Imaging Services) by reflection interference contrast
microscopy (RICM). 75 9 103 SV-LEC washed once with
PBS and resuspended in 1 ml DMEM containing 20 nM
HEPES buffer (Sigma) were seeded into a Ludin chamber
on 18 mm glass coverslips (Assistant), which have been
pre-coated with 0.01 % poly-L-lysine solution (Sigma) for
1 h at 37 C. Cell spreading was monitored by taking
RICM pictures every 5 s with a live-cell imaging micro-
scope (Axiovert 35 M, ZEISS) using red fluorescent light
(k = 565 nm), a 409 magnification and a high resolution
CCD camera (CoolSNAP EZ, Photometrics). Cell
spreading was quantified using ImageJ software and
adhesion areas were normalized to 100 %. For fibronectin
lines, the 18 mm coverslips were coated with PLL-PEG
(0.5 mg/ml, SuSoS AG) for 30 min at RT, washed one
with ddH20 followed by a second washing step with 100 %
EtOH (Reuss Chemie). Polydimethylsiloxan (PDMS) line
patterns (10 lm lines, 50 lm gaps) were cut in reasonable
size, cleaned with tape, placed on the coated coverslips and
treated for 2 min with plasma. Afterwards, line patterns
were removed, coated with fibronectin (5 lg/ll, 30 min,
RT) washed with PBS and placed into a Ludin chamber.
10 9 103 SV-LEC resuspended in 1 ml DMEM, 1 mM
Gln, 10 % FCS, 20 nM HEPES buffer were seeded into the
Ludin chamber and pictures were taken every 5 s using a
live-cell imaging microscope (Axiovert 35 M, Zeiss) at
409 magnification with a high resolution CCD camera
(CoolSNAP EZ, Photometrics).
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